NFKB1 and cancer: Moreover, our group has previously shown that co-treatment with resveratrol reduced NF-κB activation in IL-1β but not in Sirt1-ASO treated normal or cancer cells in monolayer cultures, indicating that Sirt1 suppression is not reversible at the mRNA level, emphasizing the important role of Sirt1 in the resveratrol specific signaling pathway [36,39].